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Abstract
Background: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information
at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making.
Methods: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and
intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N)
matched, pStage IIA ~ IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based
technique.
Results: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were
discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in
the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G > A:C > T transitions (76.8%) of 138
non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A
total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of
those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When
the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed
discrepant mutation profile. There were no statistically significant differences in disease free survival and overall
survival between groups showing identical mutation profiles and those with discrepancy between primary and
metastatic L/N.
Conclusions: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to
consider when interpreting genomic data based on the result of one site inspection. A large prospective study
may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients.
Keywords: Genetic heterogeneity, Mutation, Next generation sequencing, Non-small cell lung cancer, Lung
adenocarcinoma
Background
Lung cancer is a leading cause of cancer death world-
wide. In 2012, 1,824,701 new lung cancer cases were di-
agnosed and 1,590,000 patients died of this devastating
disease worldwide [1]. The discovery of oncogenic driver
mutations has contributed to the determination of the
pathogenesis of lung cancer, development of therapeutic
target agents, and prediction of treatment responses [2–4].
The identification of actionable oncogenic driver mutations
that guide selection of target agents has improved clinical
outcomes of lung cancer patients, making tumor genotyp-
ing routine clinical practice [5].
However, variable responses and eventual development
of resistant clones to target agents are critical challenges
to the drug development and therapeutic application.
Recent advances from clinical studies have led investiga-
tors to posit that targeted therapies may fail to cure on
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account of tumor heterogeneity. Tumor heterogeneity im-
plies that there are distinct morphological and phenotypic
profiles of cellular morphology, gene expression, metabol-
ism, motility, proliferation, and metastatic potential be-
tween tumors of the same type in different patients
(intertumor), and between cancer cells within a single
tumor of a patient (intratumor) [6]. Tumor heterogeneity
challenges not only the relevance of driver mutations to
the clinical outcome and to response to target therapies,
but also the development of diagnostic and therapeutic
biomarkers [7–11].
Development of heterogeneous clones inside tumors
has been modeled by cancer stem cell (CSC) models and
clonal evolution models. In the CSC model, heterogeneity
among cancer cells is the result of differences in the stem
cells from which they originate, and the variation of stem
cells is explained by (1) epigenetic changes and (2) clonal
evolution of the CSC population. On the other hand, in
the clonal evolution model, tumors arise from a single
mutated cell that accumulates diverse mutations with its
progression of time in heterogeneous microenvironment.
In the clonal evolution model, the spatial differences in
exogenous mutational pressure such as cigarette smoking
[12–15] and endogenous processes of up-regulation of
APOBEC (apolipoprotein B mRNA-editing enzyme, cata-
lytic polypeptide-like) cytidine deaminase activity con-
tribute to the regional variation in mutational burden
over time [16–18]. The spatial and temporal diversity
in lung cancer evolution is attributed to a decrease in
smoking-related mutation accompanied by an increase
in APOBEC-associated mutation [15].
The mutagenic effects of cigarette smoking are associ-
ated with C > A transversion [14] and the proportion of
C > A transversion is decreased in branched (late) muta-
tions, which is indicative of a regional heterogeneous
mutational burden attributed to smoking [15]. APOBEC
cytidine deaminase is a class of cytidine deaminases that
convert cytosine to uracil during RNA editing in the con-
text of a TCW motif (where W corresponds to either A or
T; the mutated base underlined). APOBEC-associated
mutagenesis contributes to tumor progression and a
large portion of subclonal diver mutations occur in the
APOBEC context, which eventually contributes to a differ-
ent mutational spectrum across regions and time [19].
We doubt that a biopsy at a single site represents the
genetic variation of the entire tumor. To clarify this,
genetic profiles of primary tumor and metastatic lymph
node (L/N) in the surgically resected pStage IIA-IIIA
non-small cell lung cancer (NSCLC) were compared
using next-generation sequencing (NGS)-based repeated
deep sequencing of 16 genes containing actionable onco-
genic mutations. The mutation profile of primary tumors
and corresponding metastatic L/N was examined in re-
spect of smoking related and APOBEC mediated signature.
The difference in the genetic profiles between lesions was
frequently observed in the genes that have important roles
in cancer biology and it might influence responses to
therapeutic agents.
Methods
Patient characteristics and tumor DNA samples
A total of 59 patients who met the following criteria
were randomly selected from tissue archives of affiliated
hospitals of Yonsei Medical Center: (1) a pathologically
confirmed diagnosis of pStage IIA ~ IIIA lung adenocar-
cinoma, (2) history of curative surgical resection, (3)
availability of tissues of both primary tumor and meta-
static L/N, (4) confirmation of known oncogenic driver
mutation either at ALK, EGFR, or KRAS, (5) history of
platinum-based adjuvant chemotherapy and (6) submis-
sion of informed consent for tissue collection. After ana-
lysis of NGS data, 18 cases were excluded from further
analysis because a driver mutation had not been con-
firmed at both the primary tumor and metastatic L/N.
For the extraction of cancer enriched DNA from tissue
block, paraffin-embedded tissue samples were loaded onto
silanated slides as 4-μm-thickness sections. One slide of
each block was lightly stained with H&E, re-examined for
the presence of cancer cells and then the cancer-enriched
area was marked by an independent lung pathologist. The
cancer cell-enriched areas were scrapped with blades, and
DNA was extracted using a QIAamp DNA FFPE Tissue
Kit (Qiagen, Valencia, CA, USA). This study was approved
by the ethical committee of Gangnam Severance Hospital
(IRB #3-2013-0298).
Library preparation, NGS with Ion Torrent, and variant
calling
Ten ng of gDNA was amplified by the Ion AmpliSeq™
Custom Panel (Life Technologies, Carlsbad, CA). This
panel contains 16 genes that contain actionable mutations;
AKT1, ALK, BCL2L11, BRAF, DDR2, EGFR, ERBB2,
FGFR1, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN,
ROS1, and RET [20]. The process for generating sequen-
cing data using the Ion Torrent PGM sequencer is de-
scribed elsewhere. Briefly, multiplex pools were purified
with Agencourt AMPure XP beads (Beckman Coulter
Incorporated) and ligated with Ion Xpress barcode adapters
(Life Technologies). The fragment size and quantity of each
library were analyzed with a BioAnalyzer using a High
Sensitivity Chip (Agilent, Santa Clara, CA). The library
was diluted, and emulsion PCR was performed with the
OneTouch™ reagent kit (Life Technologies). The emul-
sion PCR product was enriched using DynabeadsR
MyOneTM Streptavidin C1 beads (Life Technologies).
The final enriched ion spheres were mixed with a se-
quencing primer and polymerase and loaded onto five
318v2 chips. The libraries were sequenced with the Ion
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Torrent PGM sequencer at deep coverage (aiming for
1000×) using the Ion OneTouch 200 Template Kit v2
DL and Ion PGM Sequencing 200 Kit v2 with the 318
v2 chip kits (all from Life Technologies). The sequencing
reads were aligned to the human reference GRCh37 gen-
ome, and base calling was performed using the Ion Tor-
rent Suite V3.4.2 using tmap-f3 on the Ion Torrent server.
The Ion Torrent Variant Caller (ITVC) v3.4 was used for
the detection of mutations, requiring a frequency greater
than 5% for a variant to be called. BAM (Binary sequence
Alignment/Map format) and FASTQ files (alignment)
were generated based on the base calling results and were
used to report variant calling, including single nucleotide
polymorphisms (SNPs) and insertions/deletions (INDELs).
Statistical analysis
Categorical and continuous variables were compared
using χ2-tests and t-test, respectively. Differences in dis-
tribution of continuous variables between two independ-
ent samples were assessed by Mann–Whitney U test, and
the Kaplan–Meier estimator was used for survival analysis.
All analyses were performed with IBM SPSS Statistics ver-
sion 20 (IBM Corp.). All statistical tests were two-sided,
and a P-value <0.05 was considered to be statistically
significant.
Results
Demographic characteristics of the study population
The study cases were extracted at random from a subset
of the institutional tissue archives for which the cases
were confirmed to harbor known EGFR, KRAS, and ALK
driver mutations. This strategy was adopted based on
the hypothesis that these driver mutations are trunk mu-
tations that develop early in lung carcinogenesis and propa-
gate throughout cancer progression [11, 15]. The presence
of these mutations was used as a marker for the presence
of cancer DNA in the test samples and was also used as a
reference suggesting that a discovered mutation originated
from cancer DNA. If the EGFR, KRAS, or ALK driver mu-
tation was not confirmed both in the primary and meta-
static lesion, the case was excluded from further analysis
(Fig. 1). Eighteen of 59 cases that failed to show driver
Fig. 1 Study diagram. A total of 59 paired primary lung adenocarcinoma and corresponding lymph node metastasis with confirmed driver
mutations were randomly selected from the institutional bio-bank. We excluded 18 cases in which the known driver mutation was not detected
in both the primary and the metastatic lesion, or in cases where we were unable to generate adequate amplicons for both lesions
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mutations in the metastatic L/N were excluded from
analysis based on this prerequisite. Driver mutations in
the 41 cases were as follows: ALK rearrangement 1,
KRAS 5, and EGFR 35 pairs. The mean age of the study
population was 59.7 ± 11.06 years (range, 34–83 years).
Thirteen patients (31.7%) were male and 28 (68.3%)
were female. There was significant difference in the age
at the time of diagnosis between male and female pa-
tients. The mean age of females was 57.3 ± 10.72 and
that of males was 64.8 ± 10.49 years (P-value = 0.043, t-test).
The majority of patients (33; 80.5%) did not have a smoking
history. Three (7.3%) were current smokers and 5 (12.2%)
were ex-smokers (Table 1).
Primary tumor has a higher mutational burden than
metastatic L/N
A total of 249 mutations were discovered in the 41
paired primary and metastatic lesions, including 213
non-synonymous point mutations, 32 deletions, and 4
insertion mutations. Another four cases showed germline
deletion polymorphism of Bcl2-like11 (BCL2L11) intron 2.
There were higher chances to discover non-synonymous
point mutations in the primary tumor than in the meta-
static L/N (138 (64.8%) vs. 75 (35.2%)). Both in the pri-
mary tumor and metastatic L/N, G >A:C > T transitions
contributed to a major portion of non-synonymous point
mutations. In the sequencing data of 41 primary tumors,
Table 1 Clinical and pathologic characteristics of the study cases
n = 41













ALK fusion (n = 1)













Papillary and micropapillary predominant 8
Solid predominant with mucin production 2
Invasive mucinous adenocarcinoma 1
aFour cases harbored double EGFR driver mutations (See the Additional file 1)
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106 G > A:C > T transitions (76.8%) were discovered out
of 138 non-synonymous mutations whereas those of the
matched metastatic L/N showed 44 G >A:C > T transitions
(58.7%) from 75 non-synonymous mutations, indicating
that the proportion of the G >A:C > T transition is higher
in the primary tumors than the metastatic L/N. On the
other hands, the fraction of transversion mutation was
higher in the metastatic L/N than in the primary tumor. In
the sequencing data of primary tumor, the transversion
mutation that contributed to non-synonymous mutation
amounted to 20.3% (28 of 138), whereas in the data from
metastatic L/N, it accounted for 40.2% (29 of 75) (Table 2
and Fig. 2).
APOBEC-mediated mutagenesis is another factor that
contributes to the genetic heterogeneity of cancer and
more remarkable in the branched mutation than trunk
mutation [15]. To compare the contribution of APOBEC-
mediated mutagenesis in the primary tumor and metastatic
L/N, we evaluated APOBEC mutation signature in the
identified non-synonymous mutations. C to T and C to G
substitution in TCW motif and the complementary WGA
to WAA or WCA was defined as APOBEC signature muta-
tions [16]. A total 24 (11.3%) out of 213 non-synonymous
mutations were developed in the APOBEC signature. Of
these, 21 (87.5%) was detected in the primary tumor and 4
(16.7%) was detected in the metastatic L/N, indicating
APOBEC mediated mutation signature was more prom-
inent in the primary tumor (Additional file 1).
Heterogeneity of missense mutation between primary
and metastatic lesions is common
To illustrate the spatial heterogeneity of somatic muta-
tion of the 16 genes of the study panel, the individual
mutation of the primary tumors and the metastatic L/N
are schematized in the Table 3. In this panel depicting
genetic variation, non-synonymous mutations that were
identical between the primary and metastatic sites are
denoted in blue and those that reside either in the primary
site or metastatic lesion, indicating discrepancies, are marked
in red. Also, different mutations are located in different
row of the panel.
From 249 mutations (213 non-synonymous point
mutations, 32 deletions, and 4 insertions), 140 different
types of phenotypic changes in amino acids were identi-
fied. Mutations in EGFR accounted for a significant por-
tion of these changes, showing 31 different types of amino
acid changes, followed by MET 32, FGFR 24, NRAS and
ROS1 11 (Table 3 and Additional file 1). As it can be in-
ferred from the characteristics of the study population,
EGFR had a larger number of mutations than any other
genes in this study panel showing a total of 99 somatic
mutations in 41 paired samples. Among the detected
EGFR mutations, 37 mutations were identified both at the
primary and metastatic site, whereas 25 mutations were
identified either in the primary or metastatic site (Table 3
and Additional file 1).MET showed 46 mutations and they
were identified either in the primary tumor or metastatic
lesions, but not in both lesions, showing a 100% heteroge-
neous nature of mutation. On the other hand, MAP2K1
and BCL2L11 did not have somatic mutations. Twenty-
eight (68.3%) of 41 cases showed a mutation profile that
was exactly the same between primary and metastatic
sites, and 13 cases (31.7%) showed different mutation pro-
files. In 4 cases, different mutations were discovered either
in the primary lesion or metastatic site of paired samples.
Another 4 cases showed accumulations of new mutations
in the metastatic L/N and 5 cases showed new mutations
in the primary tumor. These findings indicate that muta-
tion of the primary lesion is not fully transferred to the
metastatic lesion.
Demographic and clinical parameters were compared
between the group with an identical mutation profile for
both primary and metastatic sites and the group with
discrepant mutation profiles (Table 4). No tested clinical
parameters were significantly different between groups.
Next, we analyzed whether the discrepancy in mutations
between the primary tumor and metastatic site influenced
the clinical outcome of the study population. When the
disease free survival (DFS) and overall survival (OS) was
compared between groups showing identical mutation
profiles and those with discrepancy between primary and
metastatic lesions, there were no statistically significant
differences in DFS and OS (Fig. 3). Collectively, differ-
ences in the mutation profiles between primary tumor
and metastatic site were common and the mutation of the
primary site was not always transferred to the metastatic
lesion. Also, these clinical parameters could not be used to
gauge spatial heterogeneity of lung cancer.
Discussion
Despite the continuous development of new therapeutic
modalities for lung cancer, the outcomes still fall short
of our expectations and a cure is seldom observed in pa-
tients treated with targeted therapy. One possible ex-
planation for the heterogeneous responses and eventual
development of resistance clones to the target agents is
the existence of various types of tumor heterogeneity.
Table 2 Non-synonymous point mutations detected in the
primary and metastatic L/N
Primary tumor Metastatic L/N Total
Transversions G > T: C > A 4 5 9
A > C: T > G 18 17 35
G > C: C > G 5 6 11
A > T: T > A 1 1 2
Transitions G > A: C > T 106 44 150
A > G: T > C 4 2 6
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Initial phenotypic heterogeneity and changes in cellular
phenotypes resulting from adaptation to response and
selection for resistant phenotypes need to be accounted
for in order to achieve substantial improvements in
therapeutic outcomes [11]. At the same time, given the
link between genetic heterogeneity and poor prognosis,
a measure of heterogeneity by itself may be useful as a
prognostic marker [11].
In this study, spatial genetic heterogeneity of lung
adenocarcinoma was compared by analyzing differences
in 16 genes with known actionable mutations between
primary and metastatic L/N. NSCLC tissues with con-
firmed EGFR, KRAS, and ALK driver mutations were
randomly selected from our institutional tissue archives.
The studies from the East Asian NSCLC patients showed
that the mutation profile of East Asian NSCLC is different
from that of Western population. Excluding the cases
without identifiable driver mutations, the mutation profile
of this study cases was EGFR 85.3%, KRAS 12.2%, and
ALK break-apart 2.4 %, which is comparable to the previ-
ous reports from East Asia. One study that recruited 1420
NSCLC patients revealed that 82 (5.8%) cases harbored
Fig. 2 Comparison of relative frequency of non-synonymous point mutations between primary lesion and metastatic lymph nodes
Table 3 Comparison of mutations between primary and metastatic L/N
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KRAS mutations either in codon 12 or 13. The low fre-
quency of KRAS mutation and high EGFR mutation rate
is consistent to the other reports from East Asia [21–25].
When a confirmed driver mutation was not validated in
both the primary lesion and metastatic lesion by the study
panel, it was excluded from further analysis, based on the
concept that these known driver mutations occur early
in cancer development and further propagates through
branched clonal evolution [15, 26–28]. Using this criter-
ion, 18 of 59 (30.5%) pairs were excluded from analysis.
This simple but conservative study design may harbor
risks that it might miss new clinically relevant mutations
in the subclones. However, it might be a useful indicator
of the presence of cancer DNA in the tissue samples mixed
with a small number of cancer cells. Indeed, a recent meta-
analysis on the differences in EGFR and KRAS mutation
between primary and corresponding metastatic NSCLC tu-
mors indicated that there is no difference between lesions
[26]. Compared to genome-wide approaches, this study
adapted a focused approach with a specific set of genes
Table 4 Clinical and pathologic characteristics of the study cases according to the heterogeneity of mutation
Homogenous (n = 28) Heterogeneous (n = 13) P-value
Age (mean ± SD); yrs 59.7 ± 12.31 59.6 ± 8.17 0.996*
Gender Male 9 4 0.930**
Female 19 9
Smoking status Never smoker 22 11 0.132**
Current smoker 1 2
Ex-smoker 5 0
pStage IIA 12 5 0.331**
IIB 0 1
IIIA 16 7
Maximum tumor diameter (cm) 3.0 ± 1.02 3.28 ± 1.15 0.401*
Histologic subtype Lepidic predominant 0 1
Acinar predominant 20 9 0.732**
Papillary and micropapillary predominant 6 2
Othersa 2 1
*P-value was obtained from t-test; **P-value was obtained from Pearson’s Chi-square test; aincludes solid types and invasive mucinous adenocarcinoma
Fig. 3 Comparison of disease-free survival (DFS) and overall survival (OS) according to the heterogeneity of non-synonymous point mutations
between primary lesion and metastatic lymph nodes. Kaplan–Meier estimation was used to compare the DFS and OS of the study population
and there was no difference in the DFS and OS in the study population that underwent curative resection
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that contain actionable mutations [6]. We also adapted se-
quencing of pooled DNA from regional sampling instead
of single cell sequencing, or longitudinal sampling ap-
proaches [11, 29–31]. This approach has limitations to the
analysis and classification of heterogeneity that may be at-
tributed to diverse causes, but it may be the most relevant
method applicable to the current medical fields.
In the primary tumor of the current smoker, where the
mutagenic pressure of cigarette smoking is stronger than
that of metastatic site, the proportion of C > A transver-
sion is higher than that of the metastatic sites [14, 15].
Interestingly, this study revealed that C > A transversion
was more frequently detected in L/N metastasis rather
than primary tumor, suggesting that other mechanisms
that cause heterogeneity exist even considering the ma-
jority of study population are composed of non-smokers.
The APOBEC deaminase activity which result in increase
of C > T:G > A and C >G:G > C mutation in the context of
TCW motif may be attributed to the different regional
accumulation of missense mutation with cancer progres-
sion [15]. This study applied less stringent condition of
APOBEC mediated mutation and showed that APOBEC
signature is more prominent in the primary tumor rather
than metastatic L/N. This can be assumed that the pri-
mary tumor has larger tumor burden with more complex
microenvironment than the metastatic site.
Genetic heterogeneity may be implicated in poor clinical
outcome. This study population did not show differences
in the DFS and OS between those with homogenous mu-
tation profile and those with heterogeneous mutation
profile. It may originate from that the study population
composed of pStage IIA-IIIA NSCLC patients treated
with curative surgical resection and adjuvant chemother-
apy based on platinum. Further studies are required on
the patients with stage IV NSCLC who are treated with
target agents.
Spatial heterogeneity, indicating that a biopsy of single
site does not represent the whole biology of cancer, may
pose significant challenges in the personalized medicine.
The cases with large tumor burden and those with treat-
ment failure require profound consideration for the num-
ber and location of target biopsy lesion, which guide
treatment planning and improve the clinical outcome of
the patients. It needs to be determined which approaches
to genetic heterogeneity lead substantial improvement in
clinical outcome in an economical way.
Conclusions
There was pronounced genetic heterogeneity in mutations
between the primary and corresponding lymph node
metastasis. The regionally separated mutations may com-
promise treatment success with a target agent in NSCLC.
It would be feasible to develop therapeutic strategies based
on a common denominator for the whole tumor, rather
than targeting a specific mutation in a gene.
Additional file
Additional file 1: Table S1. Comparion of individual mutations between
primary lesion and metastatic L/N. (XLSX 20 kb)
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